Brought to you by 
Leo Pharma gets rights to a psoriasis drug candidate from ViroBay
07 Dec 2015
Executive Summary
Leo Pharma AS (dermatology) has licensed rights to an oral psoriasis compound from ViroBay Inc. (specializes in the design of protease inhibitors) The preclinical therapeutic is set to begin Phase I studies in the last quarter of this year, and will be tested in patients in early 2013.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Leo Pharma gets rights to a psoriasis drug candidate from ViroBay
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice